Odonate's strategic focus was on creating a patient-friendly oral alternative to intravenously-administered taxanes with improved quality-of-life outcomes. The company conducted the CONTESSA Phase 3 trial for metastatic breast cancer but failed to generate approvable clinical data.
Cyborg Score Rationale
The company ceased operations in March 2021 following FDA rejection of its lead clinical program. No active development pipeline, no operations, and the company exists in a dormant or wound-down state.
Top Insights
Lead program tesetaxel failed FDA approval in March 2021 due to insufficient clinical evidence
Company was founded in 2013 and went public via IPO, but operations have ceased
Oral taxane formulation was designed to improve patient convenience versus IV alternatives
No active operations or development pipeline as of current date
Named Competitors
Taxol/Paclitaxel — IV taxane chemotherapy (gold standard)
Taxotere/Docetaxel — IV taxane chemotherapy
Recent Developments
(March 2021) Company ceased operations and closed following FDA rejection of tesetaxel clinical data
Open the full interactive Odonate Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.